Skip to search formSkip to main contentSkip to account menu

ABR-215050

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tasquinimod

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment
Tasquinimod (ABR‐215050) is an orally active quinoline‐3‐carboxamide analog that inhibits occurrence of experimental metastasis… 
2013
2013
Abstract B17: Immunomodulation by tasquinimod: Combination with immunotherapy results in enhanced CD8 T cell responses and improved antitumor effects.
Purpose: The novel anti-tumor agent tasquinimod (ABR-215050) is being developed for treatment of metastatic castration-resistant… 
2011
2011
Bioanalysis in clinical development of tasquinimod using liquid chromatography/tandem mass spectrometry.
2007
2007
An open label phase I study of ABR-215050 in patients with prostate cancer refractory to hormone therapy and with rising PSA for determination of MTD and long-term tolerability and safety
15510 Background: Preclinical studies have demonstrated that ABR-215050, an orally active 3-quinoline-carboxamide derivative with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)